General description

Native, human iC3b complement component. iC3b is formed by the cleavage of C3b by Factor I in the presence of Factor H, CR1, or membrane cofactor protein. Factor I cleavage of C3b to iC3b inactivates and prevents C3b from functioning in the C3 or C5 convertase enzymes. The iC3b fragment thus produced is a glycoprotein composed of two C3α′ polypeptides of M.W. 43 kDa and M.W. 63 kDa which are disulfide bonded to the intact C3 β-chain (M.W. 75 kDa). iC3b interaction with CR3 (CD11b/CD18) receptors present on a variety of white blood cells greatly enhances phagocytosis of iC3b coated target cells or particles.

Native, human iC3b complement component. iC3b is formed by the cleavage of C3b by Factor I in the presence of Factor H, CR1, or membrane cofactor protein. Factor I cleavage of C3b to iC3b inactivates C3b from functioning in the C3 or C5 convertase enzymes. The iC3b fragment thus produced is a glycoprotein composed of two C3α′ polypeptides of M.W. 43,000 and M.W. 63,000 are disulfide bonded to the intact C3 b-chain (M.W. 75,000). iC3b interaction with CR3 (CD11b/CD18) receptors present on a variety of white blood cells greatly enhances phagocytosis of iC3b coated target cells or particles.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Rosen, H. and Law, S.K.A. 1989. Curr. Top. Microbiol. Immunol.153, 99.Ross, G.S. and Medof, M.E. 1985. Adv. Immunol.37, 217.

Packaging

250 µg in Plastic ampoule

Please refer to vial label for lot-specific concentration.

Warning

Toxicity: Standard Handling (A)